Can-Fite BioPharma doses first patient in Phase IIa trial
The Fly

Can-Fite BioPharma doses first patient in Phase IIa trial

Can-Fite BioPharma (CANF) announces the dosing of the first patient in the Phase IIa clinical trial in patients with advanced pancreatic adenocarcinoma. “We are excited to have the first patient enrolled and hope that we will be able to demonstrate the safety and efficacy of Namodenoson in the pancreatic cancer patient population. This trial provides us the opportunity to explore our innovative treatment approach for patients who are facing significant gaps in effective treatment options,” stated Dr. Michael Silverman, Can-Fite’s Medical Officer.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App